# A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

> **NCT07111832** · PHASE3 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

## Interventions

- **DRUG:** SHR-A1811 for Injection
- **DRUG:** SHR-1316 Injection
- **DRUG:** Toripalimab Injection
- **DRUG:** Paclitaxel for Injection

## Key facts

- **NCT ID:** NCT07111832
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2028-03
- **Final completion:** 2028-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07111832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07111832, "A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07111832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*